Neratinib, an irreversible pan erB receptor tyrosine kinase inhibitor active for advanced HER2+ breast cancer

by Cortés-Funes, H, Mendiola, C, Manso, L, Ciruelos, E
Published 2009

Circulating epithelial tumor cells in patients with metastatic breast cancer treated with bevacizumab

by Manso, L, Ciruelos, E, Rodríguez, A, Diaz, J, Mendiola, C, López-Martín, JA, Cortes-Funes, H
Published 2009

Getting deep in the luminal B breast cancer subtype and its ki67 cut-off value

by Ciruelos, E, Castaneda, C, Pascual, T, Andrés, E, Gomez, HL, Manso, L, Valdivieso, N, Ghanem, I, Cortes-Funes, H
Published 2011

Lobular carcinoma of the breast: outcome of 205 patients

by Vega, E, Ciruelos, E, Valdiviezo, N, Mendiola, C, Manso, L, Ghanem, I, Dorta, M, Pascual, T, Flores, C, Cortés-Funes, H
Published 2011

Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: results of the observational “LORENA” study

by Redondo A, Ramos Vázquez M, Manso L, Gil Gil MJ, Garau Llinas I, García-Garre E, Rodríguez CA, Chacón JI, López-Vivanco G
Published 2018-09-01

Prognostic value of a high level of circulating endothelial cells in patients with HER2-recurrent or metastatic breast cancer treated with bevacizumab in combination with paclitaxe...

by Manso, L, Ciruelos, E, Codes, M, De la Haba, J, Galan, A, Baena, J, Jaen, A, Gil, M, Murias, A, Blancas, I, Gonzalez, E, Perez, D, Bayo, JL, Mel, J, Garcia-Martinez, E, Cubedo, R, Salvador, J
Published 2011